Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Intel, Leidos Advance COVID-19 Healthcare Initiatives

Leidos is fighting COVID-19 through blockchain-based data security, with help from Intel’s Pandemic Response Technology Initiative

What’s New: Leidos, a Fortune 500 science and technology leader, is using blockchain-based data security running on Intel technology to accelerate and secure contact tracing through the Centers for Disease Control and Prevention (CDC) MicrobeTrace Next platform. This project is part of Intel’s Pandemic Response Technology Initiative (PRTI), which provides grants to hundreds of ventures aimed at combatting the coronavirus through accelerated access to technology.

How It Works: Historically, contact tracing has been paper-based, requiring public health officials to fill out hard-copy forms and possibly even transcribe the data to a computer system. With the emergence of COVID-19, a need to quickly gather, analyze and report data in a timelier manner became imperative and was the genesis for transforming the CDC’s MicrobeTrace platform, with help from Leidos, First Genesis, Dell and Intel technologies.

MicrobeTrace Next supports data sharing between states and local jurisdictions, creating the potential for a secure national and regional contact tracing framework. The system enables mobile data entry and enhanced data visualization through a self-service dashboard, with all personally identifiable information protected via ransomware-resistant, blockchain-based data security. Leidos used Intel’s processor technologies built into the silicon to provide unique capabilities that improve the privacy, security and scalability of distributed ledger networks. The ability to more securely share highly sensitive and confidential information also provides field representatives and public health officials with a more efficient way to collect, transmit and analyze data more intelligently post-pandemic, to improve public health outcomes for critical diseases such as HIV.

Why It Matters: Long-standing industry challenges are even more acute in the COVID-19 pandemic. Through grants from Intel’s PRTI, projects like this are fueling technological innovations and new approaches to aid in the fight against COVID-19.

With everything moving from the edge of the network to the cloud, securing sensitive information is more important than ever. Intel’s zero trust security solutions allow business transformation in healthcare, supporting multiparty collaboration while helping maintain data privacy and regulatory compliance. Rooted in silicon, Intel hardware and software-based security create a trusted foundation for protecting data in all its phases: at rest, in flight and in use.

More Context: Intel Pandemic Response Technology Initiative (PRTI) | Intel Commits $50 Million with Pandemic Response Technology Initiative to Combat Coronavirus | Leveraging Technology to Provide Global Pandemic Relief

About Intel

Intel (Nasdaq: INTC) is an industry leader, creating world-changing technology that enables global progress and enriches lives. Inspired by Moore’s Law, we continuously work to advance the design and manufacturing of semiconductors to help address our customers’ greatest challenges. By embedding intelligence in the cloud, network, edge and every kind of computing device, we unleash the potential of data to transform business and society for the better. To learn more about Intel’s innovations, go to newsroom.intel.com and intel.com.

© Intel Corporation. Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.